Christine A. Dudzik
321 North Clark St.
Suite 3400
Chicago, IL 60654

 Download vCard

• Amgen Inc. v. Chugai Pharmaceuticals, Inc./Genetics Institute .  (D. Mass.) 927 F.2d 1200 (Fed. Cir. 1991) One of the first major biotech patent infringement cases to go to trial involving recombinant DNA, specifically, erythropoietin (rEPO), and purifying and isolating the EPO gene, where client Amgen’s patent was upheld and G.I.’s patent was invalidated for non-enablement.
• Bristol-Myers Squibb v. Ben Venue, Inc.   (D.N.J.) Represented Ben Venue in multidistrict patent infringement action under 35 USC Section 271(e)(2) (In re Research Corporation Technologies, Inc.) involving Abbreviated New Drug Application (ANDA) for chemotherapy agent where favorable Markman decision lead to finding that patent was invalid for obviousness-type double patenting.
• American Dental Assoc. Health Foundation v. Bisco, Inc.   (N.D. Ill.) Represented Bisco in a patent infringement case involving photoactive dentin bonding agents where case was settled during discovery.
• Digene v. Ventana Medical Systems.  (D. Del.) Represented plaintiff in a patent infringement action involving Human Papillomavirus (HPV) and DNA probes used in gene-based assays for the detection of cervical cancer in women. Case settled favorably for client on the eve of trial.
• American Home Products, Corp. v. The Upjohn Company .  (D.N.J.) Represented Upjohn in a patent infringement case involving canine coronia virus vaccine. Case settled during discovery.
• Digene/Qiagen v. Roche and Gen-Probe.  (ICDR Arbitration N.Y.) Representing plaintiff in an arbitration proceeding for breach of contract involving patents directed to HPV technology for use in diagnostic gene-based assays. Case is pending.
• Eltech Systems/Oxytech Systems v. PPG Industries .  (W.D. La) 903 F.2d 805 (Fed. Cir. 1990) Successfully defended PPG in patent litigation involving polymer modified asbestos diaphragms used in chlorine production. This is one of the leading cases awarding attorney fees against a patentee for bad faith litigation.
• Novo Nordisk v. Pharmacia & UpJohn .  (D.N.J.) Multiple party patent litigation involving recombinant human growth hormone (hGH) where case was favorably settled for client Pharmacia & UpJohn during discovery.
• Oakwood Laboratories, L.L.C. and University of Kentucky Research Foundation v. TAP Pharmaceuticals, Inc. and Abbott Labs.  (N.D. Ill.) Represented Plaintiffs in patent infringement case involving controlled release drug delivery system. Case favorably settled for client after 2 days of jury trial.
• ICD/Confab Industries v. The Procter & Gamble Co.   (E. D. Pa) Patent infringement case involving feminine personal products (cadamenials) where case was favorably settled on behalf of client P & G on the eve of trial.
• Stauffer Chemical Co. v. PPG Industries, Inc.   (N.D. Ohio) Successfully represented PPG in patent infringement case involving corn herbicide and chemical antidotes where case settled on first day of trial.
• Lisec v. Lenhardt Maschinenbau .  (D.N.J.) Patent infringement case involving glass transporting equipment. Case was favorably settled for client during discovery.
• TAP Holdings Inc. v. OWL Pharmaceuticals, L.L.C.   (N.D. Ohio, case pending) Patent infringement action under 35 USC Section 271(e)(2) involving Abbreviated New Drug Application (ANDA) of client Oakwood for controlled release delivery microspheres for the drug leuprolide acetate (Lupron Depot®). Recently won summary judgment of non-infringement of eight of the twelve patents in suit.
• Opposition and Appeal re: Amgen Inc. EP 237 545 .  Client Amgen’s patent to recombinant human pluripotent granulocyte-colony stimulating factor (r G-CSF) was upheld as valid in European Patent Office.
• ADAM et al. (Monsanto) v. LEEMANS et al.   U.S. Interference No. 103,924 Involved in representing Monsanto in patent interference for transgenic corn patent.
• Opposition and Appeal re: Genetics Institute, Inc. EP 209 539 .  Represented Amgen’s successful challenge to G.I.’s European patent on purified erythropoietin (EPO) where patent was found to be invalid.
• Opposition re: Chiron Corp. EP 043 911.  Successfully defended Chiron in European Opposition regarding cell culture medium where Chiron’s patent was upheld.
• The Procter & Gamble Co. v. Johnson & Johnson, Inc. and McNeil-PPC, Inc.   (D. Del/Arbitration) Represented P & G in patent infringement case involving cadamenials which favorably settled prior to arbitration.